.

LPL - LPL-ROHINI (NATIONAL REFERENCE

LAB)
SECTOR - 18, BLOCK -E ROHINI
DELHI 110085

Name : DUMMY Z891 Collected : 25/8/2020 1:13:00PM

Received : 25/8/2020 1:58:46PM
Lab No. : 152800371 Age: 39 Years Gender: Female Reported : 25/8/2020 5:32:55PM
A/c Status : P Ref By : UNKNOWN Report Status :

Test Name Results Units Bio. Ref. Interval

s
BOH (BAD OBSTETRIC HISTORY) ADVANCED PANEL

ab
LUPUS ANTICOAGULANT BY DRVVT
(Electromechanical Clot Detection)

SCREEN
Patient Value sec 36.00 - 50.00

L
Control Value sec

Screen Ratio
th <1.20

INTERPRETATION
Pa
Note
1. As per ISTH guidelines Lupus Anticoagulant detection must be done by using at least two clot based
assays employing separate clotting principles like PTT-LA & dRVVT.
2. Results of this test should always be interpreted in conjunction with the patient’s medical history,
al

clinical presentation and other findings.

3. A positive LA can be seen in otherwise normal individuals and in certain viral or other infections.
4. Once a patient has been tested positive for LA, it is imperative that testing be repeated on a second
rL

occasion > 12 weeks after the initial testing.

5. Anticoagulation therapy effects such as Warfarin (especially when the effect is supratherapeutic),
excess Heparin, direct thrombin inhibitors (DTI) (eg, Dabigatran [Pradaxa]), Argatroban [Ancova],
Bivalirudin [Angiomax]), direct factor Xa inhibitors (eg, Rivaroxaban [Xarelto], Apixaban [Eliquis],
D

Edoxaban [Savaysa]) may result in a false-positive assay performance for LA. Clinical correlation and
repeat testing after discontinuation (>1 week) of anticoagulation therapy is suggested.
6. Although the dilute Russell viper venom time (DRVVT) reagents contain a heparin inhibitor
(Polybrene) that is sufficient for neutralization of heparin (up to 1-2 U/mL), the results may not
necessarily represent what would occur if no heparin were present in the specimen. Therefore,

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*152800371*
Page 1 of 8
.

LPL - LPL-ROHINI (NATIONAL REFERENCE

LAB)
SECTOR - 18, BLOCK -E ROHINI
DELHI 110085

Name : DUMMY Z891 Collected : 25/8/2020 1:13:00PM

Received : 25/8/2020 1:58:46PM
Lab No. : 152800371 Age: 39 Years Gender: Female Reported : 25/8/2020 5:32:55PM
A/c Status : P Ref By : UNKNOWN Report Status :

Test Name Results Units Bio. Ref. Interval

DRVVT results from heparinized plasma should be interpreted with caution.

s
7. DRVVT assays, when performed in isolation, will not distinguish LA from heparin or inhibitors of

ab
factors V or VIII, which may cause false-positive results of LA testing.
8. Test conducted on Citrated plasma.

Comments

L
Lupus Anticoagulants are heterogenous IgG or IgM autoantibodies which interfere with phospholipid
dependent in vitro coagulation tests, particularly activated partial thromboplastin time (APTT). These
antibodies are associated with thrombosis (arterial & venous), recurrent abortions, neurological &
th
neuropsychiatric disorders. Various methods for testing Lupus Anticoagulants include PTT-LA, activated
kaolin clotting time and dilute Russels Viper Venom time. Out of these the DrVVT assay is the most robust &
specific because DrVVT is not influenced by deficiencies of intrinsic pathway or antibodies to factors VIII, IX or
Pa
XI.

TORCH PANEL EXTENDED, IgG & IgM, SERUM

(CLIA, EIA)

Toxoplasma, IgG IU/mL <7.20

al

Toxoplasma, IgM AU/mL <10.00

Rubella, IgG IU/mL <10.00

rL

Rubella, IgM AU/mL <20.00

Cytomegalovirus, IgG AU/mL <12.00

U/mL <18.00
D

Cytomegalovirus, IgM

Herpes simplex virus 1, IgG Index <0.90

Herpes simplex virus 1, IgM Index <0.80

Herpes simplex virus 2, IgG Index <0.90

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*152800371*
Page 2 of 8
.

LPL - LPL-ROHINI (NATIONAL REFERENCE

LAB)
SECTOR - 18, BLOCK -E ROHINI
DELHI 110085

Name : DUMMY Z891 Collected : 25/8/2020 1:13:00PM

Received : 25/8/2020 1:58:46PM
Lab No. : 152800371 Age: 39 Years Gender: Female Reported : 25/8/2020 5:32:55PM
A/c Status : P Ref By : UNKNOWN Report Status :

Test Name Results Units Bio. Ref. Interval

Herpes simplex virus 2, IgM Index <0.80

s
ab
Interpretation
---------------------------------------------------------------------------
| INFECTION | UNITS | NEGATIVE | EQUIVOCAL | POSITIVE |
|----------------|------------|---------------|-----------------|------------|
| Toxoplasma IgG | IU/mL | <7.20 | 7.20-<8.80 | ≥8.80 |
|----------------|------------|---------------|-----------------|------------|
| Rubella IgG | IU/mL | <10.00 | - | ≥10.00 |

L
|----------------|------------|---------------|-----------------|------------|
| CMV IgG | U/mL | <12.00 | 12.00 -<14.00 | ≥14.00 |
|----------------|------------|---------------|-----------------|------------|
| HSV 1, IgG | Index | <0.90
th | >0.90-<1.10 | ≥1.10 |
|----------------|------------|---------------|-----------------|------------|
| HSV 2, IgG | Index | <0.90 | 0.90-<1.10 | ≥1.10 |
|----------------|------------|---------------|-----------------|------------|
| Toxoplasma IgM | AU/mL | <10.00 | - | ≥10.00 |
Pa
|----------------|------------|---------------|-----------------|------------|
| Rubella IgM | AU/mL | <20.00 | 20.00-<25.00 | ≥25.00 |
|----------------|------------|---------------|-----------------|------------|
| CMV IgM | U/mL | <18.00 | 18.00-<22.00 | ≥22.00 |
|----------------|------------|---------------|-----------------|------------|
| HSV 1, IgM | Index | <0.80 | 0.80-1.20 | >1.20 |
|----------------|------------|---------------|-----------------|------------|
| HSV 2, IgM | Index | <0.80 | 0.80-1.20 | >1.20 |
---------------------------------------------------------------------------
al

TORCH Extended IgG

rL

1. This assay is used for quantitative detection of specific IgG antibodies to TORCH in serum samples.
2. Positive result indicates past infection with TORCH. Pregnant females with positive TORCH specific
IgG antibodies are considered to be immune and hence risk of transmission of infection to fetus is
minimal.
3. Equivocal results should be re-tested in 10-14 days.
D

4. Negative result indicates person has not been exposed to TORCH in the past. Pregnant females with
negative TORCH specific IgG antibodies are considered at risk of transmission of infection to fetus .
Patients with negative results in suspected disease should be re -tested after 10-14 days. False
negative results can be due to immunosuppression or due to low/undetectable level of IgG antibodies.
5. To differentiate between recent and past infection, Toxoplasma, Rubella & CMV IgG avidity test is
indicated.
6. Demonstration of rising antibody titer (four folds) in acute and convalescent sera taken 2-3 weeks
PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*152800371*
Page 3 of 8
.

LPL - LPL-ROHINI (NATIONAL REFERENCE

LAB)
SECTOR - 18, BLOCK -E ROHINI
DELHI 110085

Name : DUMMY Z891 Collected : 25/8/2020 1:13:00PM

Received : 25/8/2020 1:58:46PM
Lab No. : 152800371 Age: 39 Years Gender: Female Reported : 25/8/2020 5:32:55PM
A/c Status : P Ref By : UNKNOWN Report Status :

Test Name Results Units Bio. Ref. Interval

apart are indicative of TORCH infection.

s
7. The result should be interpreted in conjunction with clinical finding and other diagnostic tests. The
magnitude of the measured result is not indicative of the amount of antibody present.

ab
TORCH Extended IgM

1. This assay is used for quantitative detection of specific IgM antibodies to TORCH in serum samples.

L
2. Positive result for TORCH IgM indicates possible acute infection with TORCH. False positive reaction
due to rheumatoid factor and persistence of positive IgM (except Herpes Simplex virus) for upto 2
th
years is not uncommon.
3. An equivocal result requires repeat testing in 10-14 days.
4. Negative result indicates no serological evidence of infection with TORCH. False negative can be due
to immunosuppression or due to low/undetectable level of IgM antibodies. A suspected diagnosis of
Pa
acute TORCH infection should be confirmed by PCR analysis or repeat test after 10-14 days.
5. The diagnosis should not be established on the basis of single test and the results should be
interpreted in conjunction with clinical findings.
6. The magnitude of the measured result is not indicative of the amount of antibody present.

Comments
al

Perinatal infections account for 2-3% of all congenital anomalies. TORCH which includes Toxoplasma,
Rubella, Cytomegalovirus & Herpes Simplex virus, are some of the most common infections associated
with Congenital anomalies. Most of the TORCH infections cause mild maternal morbidity, but have serious
fetal consequences. Reliable recognition of acute infection is highly important in pregnant women.
rL

IgM-positive result alone does not accurately predict the risk of fetal infection; a positive IgM test should
therefore be considered only as a starting point and a more thorough diagnostic evaluation is necessary to
determine whether there is a risk of fetal infection. Primary CMV infection may result in establishment of
persistent or latent infection. In man the infection is usually asymptomatic. Infections can be acquired through
direct contact with individuals shedding the virus. Once HSV infection occurs, it persists in a latent state in
D

sensory ganglia from where it may re-emerge to cause periodic recurrence of infection induced by many
stimuli, which may or may not result in clinical lesions. Demonstration of Toxoplasma IgG in the serum of
person with eye lesion helps in diagnosing ocular toxoplasmosis while persistent or increasing IgG antibody
levels in the infant compared with the mother and/or positive result of Toxoplasma specific IgM or IgA are
diagnostic of Congenital toxoplasmosis. Demonstration of rising antibody titer (four folds) in acute and
convalescent sera taken 2-3 weeks apart are indicative of postnatal Rubella infection and to check response
to Rubella vaccination. Single test results of CMV IgG are useful in screening organ transplant recipients and
donors before transplantation and donors of blood products that are to be administered to premature infants
PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*152800371*
Page 4 of 8
.

LPL - LPL-ROHINI (NATIONAL REFERENCE

LAB)
SECTOR - 18, BLOCK -E ROHINI
DELHI 110085

Name : DUMMY Z891 Collected : 25/8/2020 1:13:00PM

Received : 25/8/2020 1:58:46PM
Lab No. : 152800371 Age: 39 Years Gender: Female Reported : 25/8/2020 5:32:55PM
A/c Status : P Ref By : UNKNOWN Report Status :

Test Name Results Units Bio. Ref. Interval

and bone marrow transplant patients. Positive result of HSV (1/2) IgG indicates past infection with Herpes

s
Simplex virus or administration of HSV immunoglobulins. Reliable recognition of acute infection is highly
important in pregnant women. IgM-positive result alone does not accurately predict the risk of fetal infection; a

ab
positive IgM test should therefore be considered only as a starting point and a more thorough diagnostic
evaluation is necessary to
ANTI NUCLEAR ANTIBODY / FACTOR (ANA/ANF), Units <20.00
SERUM
(EIA)

L
Interpretation
---------------------------------------------
| RESULT IN UNITS | REMARKS |

| Negative
th
|-------------------|-------------------------|
| <20
|-------------------|-------------------------|
|

| 20-60 | Moderate positive |

|-------------------|-------------------------|
Pa
| >60 | Strong positive |
---------------------------------------------

Comments
Antinuclear antibodies are the most sensitive screening test for autoantibodies in patients suspected of
connective tissue diseases. They are a heterogenous group of autoantibodies directed against ds-DNA,
histones, SSA / Ro, SSB / La, Sm, Sm / RNP, Scl-70, Jo-1 & Centromere. ANA ‘s have also been detected in
al

patients with Autoimmune Hepatitis (80%),Primary biliary cirrhosis (60%), Alcohol related liver disease (50%),
Viral hepatitis B (40%). Presence of ANA has also been detected in individuals taking certain drugs like
Hydrallazine, Isoniazid, Chlorpromazine; family of SLE patients; healthy and elderly persons
rL

CARDIOLIPIN ANTIBODY, IgA ,SERUM APL <12.00

(EIA)
D

Interpretation
---------------------------------------------
| RESULT IN APL | REMARKS |
|-------------------------|-------------------|
| <12 | Negative |
|-------------------------|-------------------|
| 12-20 | Equivocal |
|-------------------------|-------------------|
| 20-80 | Low Positive |
|-------------------------|-------------------|
| >80 | High Positive |
PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*152800371*
Page 5 of 8
.

LPL - LPL-ROHINI (NATIONAL REFERENCE

LAB)
SECTOR - 18, BLOCK -E ROHINI
DELHI 110085

Name : DUMMY Z891 Collected : 25/8/2020 1:13:00PM

Received : 25/8/2020 1:58:46PM
Lab No. : 152800371 Age: 39 Years Gender: Female Reported : 25/8/2020 5:32:55PM
A/c Status : P Ref By : UNKNOWN Report Status :

Test Name Results Units Bio. Ref. Interval

---------------------------------------------

s
Comments

ab
Anticardiolipin antibodies(ACA) belong to the group of Antiphospholipid antibodies which are positive in
30-40% cases of Systemic lupus erythematosus and also in patients with other Rheumatic diseases.
Presence of cardiolipin antibodies is considered to be of significant diagnostic relevance in cases of
Venous/Arterial thrombosis, Thrombocytopenia, Livedo reticularis, Habitual abortions and Neurological
manifestations. Elevated ACA levels are also seen in patients with Cardiovascular insufficiency and

L
Myocardial infarction .

CARDIOLIPIN ANTIBODY, IgG, SERUM

(EIA)
th GPL <15.00

CARDIOLIPIN ANTIBODY, IgM, SERUM MPL <12.50

(EIA)
Pa
TSH, ULTRASENSITIVE, SERUM uIU/mL 0.550 - 4.780
(CLIA)
al
rL
D

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*152800371*
Page 6 of 8
.

LPL - LPL-ROHINI (NATIONAL REFERENCE

LAB)
SECTOR - 18, BLOCK -E ROHINI
DELHI 110085

Name : DUMMY Z891 Collected : 25/8/2020 1:13:00PM

Received : 25/8/2020 1:58:46PM
Lab No. : 152800371 Age: 39 Years Gender: Female Reported : 25/8/2020 5:32:58PM
A/c Status : P Ref By : UNKNOWN Report Status :

Test Name Results Units Bio. Ref. Interval

s
PHOSPHOLIPID ANTIBODIES PANEL, IgG & IgM, SERUM
(EIA)
IgG GPL U/mL <10.00

ab
IgM MPL U/mL <10.00

2006 International Consensus statement on Classification of definite APS

L
--------------------------------------------------------------
| Clinical Criteria | Laboratory Criteria |
|----------------------------|---------------------------------|
| Arterial/Venous thrombosis | Cardiolipin antibodies (aCL) |
| Fetal Loss
th
|----------------------------|---------------------------------|
| Beta 2 Glycoprotein 1 Antibodies|
|----------------------------|---------------------------------|
| Premature birth | Lupus Anticoagulant (LA) |
--------------------------------------------------------------
Note: APS is established if at least 1 Laboratory criteria and 1 Clinical criteria are met. The Laboratory criteria
Pa
should be present on two or more occasions 12 weeks apart for diagnosing APS.

Comments
Phospholipid antibody is a quantitative assay to screen the presence of autoantibodies against cardiolipin,
phosphatidyl serine, phosphatidyl inositol & phosphatidic acid in the diagnosis of an increased risk of
thrombosis in patients with Systemic lupus erythematosus (20-35%) and other lupus like disorders.
al

This test is also used to diagnose Anti-phospholipid syndrome in patients with recent miscarriage ( 11-22% in
all trimesters), Pulmonary hypertension, Non-vegetative endocarditis, Livedoreticularis, Stroke at young age
and Deep vein thrombosis.
rL
D

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

Page 7 of 8

*152800371*
.

LPL - LPL-ROHINI (NATIONAL REFERENCE

LAB)
SECTOR - 18, BLOCK -E ROHINI
DELHI 110085

Name : DUMMY Z891 Collected : 25/8/2020 1:13:00PM

Received : 25/8/2020 1:58:46PM
Lab No. : 152800371 Age: 39 Years Gender: Female Reported : 25/8/2020 5:32:58PM
A/c Status : P Ref By : UNKNOWN Report Status :

Test Name Results Units Bio. Ref. Interval

s
ab
Dr Ritu Nayar Dr Shalabh Malik Dr.Kamal Modi Dr Anil Arora
MD, Microbiology MD, Microbiology MD, Biochemistry MD, Pathology
Deputy HOD - Microbiology & Serology National Head - Microbiology & Consultant Biochemist HOD Hematology &
NRL - Dr Lal PathLabs Ltd Serology NRL - Dr Lal PathLabs Ltd Immunohematology
NRL - Dr Lal PathLabs Ltd NRL - Dr Lal PathLabs Ltd

L
Dr Himangshu Mazumdar
MD, Biochemistry
Senior Consultant - Clinical Chemistry
& Biochemical Genetics
th
Dr Nimmi Kansal
MD, Biochemistry
National Head - Clinical Chemistry &
Biochemical Genetics
Dr Parul Chopra
MD, Laboratory Medicine
Consultant
NRL - Dr Lal PathLabs Ltd
Dr Sunanda
MD, Pathology
Consultant
NRL - Dr Lal PathLabs Ltd
NRL - Dr Lal PathLabs Ltd NRL - Dr Lal PathLabs Ltd
Pa
Result/s to follow:
LUPUS ANTICOAGULANT BY DRVVT, TORCH PANEL EXTENDED, IgG & IgM, SERUM, ANTI NUCLEAR ANTIBODY /
FACTOR (ANA/ANF), SERUM, CARDIOLIPIN ANTIBODY, IgA ,SERUM, CARDIOLIPIN ANTIBODY, IgG, SERUM,
CARDIOLIPIN ANTIBODY, IgM, SERUM, PHOSPHOLIPID ANTIBODIES PANEL, IgG & IgM, SERUM, TSH,
ULTRASENSITIVE, SERUM

IMPORTANT INSTRUCTIONS
al

*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
rL

circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.
D

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 6)

Page 8 of 8

*152800371*